Ouster Inc

This advisory (non-binding) say-on-pay proposal asks stockholders to approve the overall compensation of the named executive officers as disclosed in the proxy statement. Management is seeking this vote to provide shareholders an opportunity to express their views on compensation philosophy, policies, and the aggregate pay outcomes for the year, and to inform future pay decisions by the Compensation Committee. The company states that its 2025 compensation programs were effective incentives aligned with stockholder interests and that the Compensation Committee will consider the vote's outcome when setting future pay. The vote does not bind the Board or management but serves as a gauge of shareholder sentiment and a mechanism for accountability. In context, the company reported strong shareholder support in 2025 (approximately 94.1% FOR), and it commits to annual say-on-pay votes. Key considerations for analysts include the composition of pay (significant equity awards and performance-based bonuses), the recent remediation of material weaknesses (which may affect governance perceptions), and the Compensation Committee’s use of consultants (Semler Brossy). Potential risks include misalignment between realized pay and performance metrics, dilution from large equity grants, and possible shareholder dissatisfaction if pay outcomes diverge from performance. Management emphasizes alignment of targets and pay and retention of executives through equity; analysts should assess the degree to which realized compensation reflects company performance (e.g., TSR and net loss trends) and whether governance mechanisms (clawbacks, compensation recovery policy) mitigate excessive risk-taking. The Board recommends a FOR vote, framing the proposal as consistent with investor dialogue and sound compensation practice, but investors should weigh the non-binding nature of the vote against factual pay-for-performance metrics and the company’s disclosure on pay rationale.

This proposal requests shareholder approval for an amendment to the Certificate of Incorporation to increase authorized common shares from 100 million to 200 million. Management frames the amendment as providing flexibility to support financings, equity compensation, stock dividends or splits, conversions, strategic transactions, and at-the-market offerings without the delay and expense of convening a special stockholder meeting. If approved, the company would file a Certificate of Amendment reflecting the new Article IV authorizing 200 million common shares and 100 million preferred shares. The Board asserts there are no immediate issuances planned beyond shares already reserved for incentive plans and the ESPP, but notes directors and officers with outstanding awards may have an indirect interest because future awards could require additional authorized shares. The potential dilutive effect from future issuances is acknowledged — impacting EPS, book value, and voting power — and the Board discloses that the amendment could in some circumstances be used defensively, although it is not proposed with an anti-takeover intent. For analysts, the key governance considerations are scope of discretion granted to the Board to issue shares without further shareholder approval, the company’s capital needs (e.g., working capital, M&A, ATM program usage), and the historic and projected share reserve burn rates; monitoring post-approval issuance activity will be important. The Board recommends a FOR vote citing strategic flexibility as the rationale, but investors should weigh the company’s capital plan, dilution sensitivity, and any potential use of authorized shares that could disadvantage current holders.

This proposal seeks shareholder approval to add an Article to the Certificate of Incorporation that would exculpate Covered Officers from monetary liability for breaches of the duty of care to the fullest extent permitted by Delaware law (Amended Section 102(b)(7)). Management argues the amendment will aid recruitment and retention of senior officers, align officer protections with those already available to directors, and reduce the distraction and cost of defending hindsight-based claims. The amendment expressly does not limit liability for duty of loyalty breaches, bad-faith or intentional misconduct, knowing violations of law, transactions conferring improper personal benefit, or derivative claims brought in the corporation’s name, and applies only to direct stockholder claims as permitted by DGCL. The board has adopted the Exculpation Amendment and will file a Certificate of Amendment if approved, but retains discretion to delay or abandon filing. Governance considerations include the expansion of officer protections in a more litigious environment and the trade-off between officer shielded risk and shareholder legal recourse; while limiting care-based liability may encourage bold decision-making, it may also reduce accountability for negligent conduct. Analysts should assess the company’s existing governance safeguards (e.g., oversight, audit, compliance), the scope of officers covered (presidents, CFO, identified high-compensated officers, or those who consent to service), and potential insurance/backstops that could offset reduced private enforcement. The Board recommends FOR, citing competitive recruiting and operational decision-making benefits, but stockholders should weigh whether exculpation is necessary given existing protections and whether it might diminish deterrence against poor oversight.